samadder banner

Our Research

Our research focuses on the early detection and prevention of colorectal cancer.

Our studies have assessed the increased risk of colorectal cancer associated with various genetic, lifestyle factors (smoking, alcohol consumption) and chronic diseases (diabetes, inflammatory bowel disease) and opportunities for chemoprevention (NSAID and statin use). He has recently been awarded Career Development Awards from both the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG). Recent research projects have been presented at the Presidential Plenary Sessions at both the American College of Gastroenterology meeting (October 2012) and Digestive Diseases Week (May 2013).

Our research techniques include:

  • Prospective/retrospective observational studies
  • Administrative databases - Utah Population Database
  • Meta-analysis
  • Outcomes research

Active & Pending Projects

Utah Population Database (UPDB)

  • Predictors of Missed and Interval Colorectal Cancer in Utah - Funding from the American Society for Gastrointestinal Endoscopy
  • Molecular Predictors of Missed and Interval Colorectal Cancer - Funding from the American College of Gastroenterology and American Gastroenterological Association Career Development Awards

Iowa Women’s Health Cohort Study (IWHS)

  • Clinical & Pathologic Features associated with CRC Molecular Pathways
  • Cigarette Smoking and CRC Risk by KRAS mutation status in older women
  • Cigarette Smoking, Alcohol use and Colorectal Adenoma risk in older women
  • Diabetes status and Colorectal Adenoma risk in older women

Molecular Epidemiology of Colorectal Cancer Study (MECC)

  • Inflammatory Bowel Disease and risk of CRC and modification by statin use.
Chemoprevention
  • Chemoprevention of gastrointestinal cancer in patients with familial adenomatous polyposis. Phase 2 randomized double blind trial of Erlotinib and Sulindac versus placebo for regression of duodenal neoplasia in FAP.  Funded by NCI.
  • Cancer Prevention Pharmaceuticals (CPP) DFMO/Sulindac in patients with familial adenomatous polyposis.  Phase 3 randomized double blind study.  Funded by CPP.
  • Phase 1 clinical chemoprevention trial and biomarker discovery using Naproxen in patients with mismatch repair deficiency/Lynch syndrome. Funded by NCI.
  • Erlotinib dose ranging Phase 2 chemoprevention clinical trial in FAP duodenal neoplasia. Funding by NCI.